Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.
Rani BurmPanagiota MaraveliaGustaf AhlenSandra CiesekNoelia Caro PerezAnna PasettoStephan UrbanFreya Van HoutteLieven VerhoyeHeiner WedemeyerMagnus JohanssonLars FrelinMatti SällbergPhilip MeulemanPublished in: Gut (2022)
The herein described preS1-HDAg immunotherapy is shown to be immunogenic and vaccine-induced antibodies are highly effective at preventing HBV and HDV (super)infection both in vitro and in vivo. Our vaccine can complement current and future therapies for the control of chronic HBV and HDV infection.